- Home
- GDEV vs OABI Comparison
GDEV vs OABI Comparison
Compare GDEV & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- OABI
- Stock Information
- Founded
- GDEV 2009
- OABI 2012
- Country
- GDEV Cyprus
- OABI United States
- Employees
- GDEV N/A
- OABI N/A
- Industry
- GDEV EDP Services
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- OABI Health Care
- Exchange
- GDEV Nasdaq
- OABI Nasdaq
- Market Cap
- GDEV 427.5M
- OABI 429.6M
- IPO Year
- GDEV N/A
- OABI N/A
- Fundamental
- Price
- GDEV $18.60
- OABI $3.21
- Analyst Decision
- GDEV Buy
- OABI Strong Buy
- Analyst Count
- GDEV 2
- OABI 4
- Target Price
- GDEV $70.00
- OABI $9.00
- AVG Volume (30 Days)
- GDEV 5.0K
- OABI 483.2K
- Earning Date
- GDEV 11-14-2024
- OABI 11-12-2024
- Dividend Yield
- GDEV N/A
- OABI N/A
- EPS Growth
- GDEV N/A
- OABI N/A
- EPS
- GDEV 2.04
- OABI N/A
- Revenue
- GDEV $432,534,000.00
- OABI $20,409,000.00
- Revenue This Year
- GDEV N/A
- OABI N/A
- Revenue Next Year
- GDEV $9.01
- OABI $78.61
- P/E Ratio
- GDEV $9.14
- OABI N/A
- Revenue Growth
- GDEV N/A
- OABI N/A
- 52 Week Low
- GDEV $17.47
- OABI $3.16
- 52 Week High
- GDEV $42.76
- OABI $6.55
- Technical
- Relative Strength Index (RSI)
- GDEV 40.40
- OABI 31.99
- Support Level
- GDEV $17.47
- OABI $3.16
- Resistance Level
- GDEV $19.00
- OABI $3.37
- Average True Range (ATR)
- GDEV 0.71
- OABI 0.14
- MACD
- GDEV 0.23
- OABI -0.03
- Stochastic Oscillator
- GDEV 40.94
- OABI 7.55
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.